Clinical Efficacy of Moxifloxacin in the Treatment of Bacterial Keratitis. A Randomized Clinical Trial

Ophthalmology

Volumn 114, Issue 9, 2007, Pages 1622-1629

  Constantinou, Marios ^a,b   Daniell, Mark ^a,b   Snibson, Grant R ^a,b   Vu, Hien T ^b   Taylor, Hugh R ^a,b  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BENZALKONIUM CHLORIDE; CEFAZOLIN; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLOXACILLIN; GATIFLOXACIN; MOXIFLOXACIN; NEOMYCIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; BACTERIAL STRAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVA ULCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA ULCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENUCLEATION; EYE DISCOMFORT; FEMALE; HUMAN; KERATITIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIA; CEFAZOLIN; CHILD; CORNEA; CORNEAL ULCER; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PROSPECTIVE STUDIES; QUINOLINES; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 34548239710     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.12.011     Document Type: Article

References (36)

1. Morlet N., and Daniell M. Microbial keratitis: what's the preferred initial therapy?. View 2: empirical fluoroquinolone therapy is sufficient initial treatment. Br J Ophthalmol 87 (2003) 1169-1172
2. Asbell P., and Stenson S. Ulcerative keratitis: survey of 30 years' laboratory experience. Arch Ophthalmol 100 (1982) 77-80
3. Baum J.L., and Barza M. Infections of the eye. In: Gorbach S.L., Bartlett J.G., and Blacklow N.R. (Eds). Infectious Diseases. 2nd ed. (1998), W.B. Saunders, Philadelphia 1355-1373
4. Coster D.J., and Badenoch P.R. Host, microbial and pharmacological factors affecting the outcome of suppurative keratitis. Br J Ophthalmol 71 (1987) 96-101
5. Jones D.B. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol 24 (1979) 105-116
6. McDonnell P.J., and Green W.R. Keratitis. In: Mandell G.L., Gordon Jr. R.G., and Bennet J.E. (Eds). Principles and Practice of Infectious Diseases. 3rd ed. (1990), Churchill Livingstone, New York 981-987
7. Ostler H.B. Corneal infections. In: Hoeprich P.D., and Jordon M.C. (Eds). Infectious Diseases: A Modern Treatise of Infectious Processes. 4th ed. (1989), Lippincott, Philadelphia 1443-1447
8. Baum J.L. Initial therapy of suspected microbial corneal ulcers. I. Broad antibiotic therapy based on prevalence of organisms. Surv Ophthalmol 24 (1979) 97-105
9. Judson P.H. Aminoglycoside macular toxicity after subconjunctival injection: case report. Arch Ophthalmol 167 (1989) 1282-1283
10. Wilhelmus K.R., Hyndiuk R.A., Caldwell D.R., et al. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthalmol 111 (1993) 1210-1218
11. O'Brien T.P., Maguire M.G., Fink N.E., et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 113 (1995) 1257-1265
12. Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. Ophthalmology 104 (1997) 1902-1909
13. Garg P., Sharma S., and Rao G.N. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 106 (1998) 1319-1323
14. Goldstein M.H., Kowalski R.P., and Gordon Y.J. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 106 (1999) 1313-1318
15. Jones D.B. Polymicrobial keratitis. Trans Am Ophthalmol Soc 79 (1981) 153-162
16. Laibson P.R. Cornea and sclera. Arch Ophthalmol 88 (1972) 553-574
17. Liesegang T.J., and Forster R.K. Spectrum of microbial keratitis in South Florida. Am J Ophthalmol 90 (1980) 38-47
18. Baum J.L. Current concepts in ophthalmology: ocular infections. N Engl J Med 299 (1978) 28-31
19. Hyndiuk R.A. Experimental Pseudomonas keratitis. Trans Am Ophthalmol Soc 79 (1981) 541-624
20. Freedman H., and Sugar J. Pseudomonas keratitis following cosmetic soft contact lens wear. Contact Lens J 10 (1976) 21-25
21. Wilson L.A., Schliltzer R.L., and Ahearn D.G. Pseudomonas corneal ulcers associated with soft contact-lens wear. Am J Ophthalmol 82 (1981) 546-554
22. Musch D.C., Sugar A., and Meyer R.F. Demographic and predisposing factors in corneal ulceration. Arch Ophthalmol 101 (1983) 1545-1548
23. Hyndiuk R.A., Eiferman R.A., Caldwell D.R., et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology 103 (1996) 1854-1862 discussion 1862-3
24. Glasser D.B., Gardner S., Ellis J.G., and Pettit T.H. Loading doses and extended dosing intervals in topical gentamycin therapy. Am J Ophthalmol 99 (1985) 329-332
25. Rolando M., Brezzo V., Campagna P., et al. Toxic effects of antimicrobials on the ocular surface of healthy volunteers. Chibret Int J Ophthalmol 8 (1991) 46-50
26. Blondeau J.M. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones.". J Antimicrob Chemother 43 suppl (1999) 1-11
27. Dalhoff A., Petersen U., and Endermann R. In vitro activity of Bay 12 8039, a new 8 methoxyquinolone. Chemotherapy 42 (1996) 410-425
28. Tankovic J., Bachoual R., Ouabdesselam S., et al. In-vitro activity of moxifloxacin against fluoroquinolone resistant strains of aerobic Gram negative bacilli and Enterococcus faecolis. J Antimicrob Chemother 43 suppl (1999) 19-23
29. Barry A.L., Fuchs P.C., and Brown S.D. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Eur J Clin Microbiol Infect Dis 18 (1999) 305-309
30. Schedletzky H., Wiedemann B., and Heisig P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 43 suppl (1999) 31-37
31. Mallari P.L., McCarty D.J., Daniel M., and Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol 131 (2001) 131-133
32. Daniell M., Constantinou M., Vu H.T., and Taylor H.R. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 90 (2006) 461-464
33. Akpek E.K., Dart J.K., Watson S., et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 111 (2004) 476-482
34. Hingorani M., Moodaley L., Calder V.L., et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 105 (1998) 1715-1720
35. Kowalski R.P., Dhaliwal D.K., Karenchak L.M., et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136 (2003) 500-505
36. Gangopadhyay N., Daniell M., Weih L., and Taylor H.R. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol 84 (2000) 378-384